DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1777)

Systemic Lupus Erythematosus | Landscape & Forecast | Disease Landscape & Forecast

Systemic Lupus Erythematosus | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

SLE is an autoimmune condition characterized by varied symptoms and multiple organ involvement, making it a complex disease that is difficult to manage. Moreover, challenges in clinical trial design and in understanding the potential market for SLE therapies often impede drug development, leading to high failure rates of pipeline agents. Benlysta is the only approved biologic for SLE, which caters to a specific SLE population, leaving high unmet need in the SLE space. Pharmaceutical companies have identified the hidden commercial opportunity in this area, as such,the SLE pipeline has several agents in late-phase and many more in early-phase development. The SLE Disease Landscape & Forecast offers detailed insights into current medical practices, key unmet needs, and new developments in the SLE space, along with an analysis of opportunities and obstacles faced by emerging agents.

Questions Answered:

  • How large is the drug-treated SLE population and how will it change over the 2017-2027 forecast period?
  • How large is the treatable SLE population and how will diagnosis/drug-treatment rates change over time?
  • What is the state of treatment in SLE? Which are the most important drugs and why? What are interviewed experts’ insights on current treatment options? What are the key unmet needs in SLE?
  • Which novel therapies are most promising and what sales/uptake could they secure in SLE? What therapies of note are progressing in earlier phases?
  • What are the drivers and constraints in the SLE market and how will the market evolve over the forecast period?


Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: Approximately 30 country-specific interviews with rheumatologists and nephrologists.

Epidemiology: Diagnosed prevalence of SLE by country and subpopulations (nonrenal SLE and lupus nephritis).

Population segments in market forecast: Total population, nonrenal SLE population, renal SLE (LN) population.

Emerging therapies: Phase II: 16 drugs; Phase III: 5 drugs; Coverage of 6 select preclinical and Phase I products.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • November 2018
      • August 2018
      • June 2018
      • November 2017
      • September 2017
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Systemic Lupus Erythematosus?
        • What Factors Are Constraining the Market for Systemic Lupus Erythematosus?
      • Drug-Class-Specific Trends
        • Antimalarials
        • Immunosuppressants/Cytotoxic Drugs
        • Corticosteroids
        • B-Cell Modulators
        • Interferon-Alpha Inhibitors
        • Interleukin-12/23 Inhibitors
        • Jak Inhibitors
    • Forecast
    • Etiology and Pathophysiology
      • Disease Overview
        • Disease Overview
      • Etiology
      • Pathophysiology
        • Clinical Manifestations
        • Disease Severity
        • Pathogenesis
      • Key Pathways and Drug Targets
        • B cells
        • T cells
        • Tissue Damage
        • Abnormal Cytokine and Chemokine Expression
    • Epidemiology Overview
      • Key Findings
        • Key Updates
      • Epidemiology Populations
        • Diagnosed Prevalent Cases
        • Subpopulations
        • Drug-Treated Cases of Systemic Lupus Erythematosus
    • Current Treatment Overview
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Antimalarials
        • Corticosteroids
        • Immunosuppressants and Cytotoxics
        • B-Cell Modulators
      • Medical Practice
        • Overview
        • Treatment Guidelines
        • Drug Selection
        • Country-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Systemic Lupus Erythematosus
    • Emerging Therapies Overview
      • Key Findings
      • Notable Developments in the Late-Phase Pipeline for Systemic Lupus Erythematosus
      • Key Emerging Therapies
        • B-Cell Modulators
        • IL 12/23 Inhibitors
        • Jak Inhibitors
        • Interferon-Alpha Inhibitors
        • Calcineurin Inhibitors
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Systemic Lupus Erythematosus
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Systemic Lupus Erythematosus Bibliography

Already a Client? Log in to access this report.

  • Pub Date: November 2018
  • Author(s): Mohit Nasa, MBA; Sunali D. Goonesekera, SM
  • Mohit Nasa is a Lead Insights analyst on the Immune and Inflammatory team at Decision Resources Group and has authored content for indications like asthma and rheumatoid arthritis. He holds a Bachelor’s degree in Pharmacy and has earned his MBA in marketing and CRM from Amity Business School. Prior to joining DRG, Mohit worked as a Senior Business analyst at Novartis where he was responsible for end to end market assessment, reporting analytics and related projects for Novartis’s asthma brand Xolair. Mohit has also worked as Brand Manager at Ozone pharma and an Account Manager for IMS Health.

  • Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group. Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.

Purchase Report

Recent reports:
You may also be interested in: